Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07776782
PHASE1

A Phase 1 Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants

Sponsor: Mirador Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MT-201 Administered with Concomitant Infliximab in Healthy Participants

Official title: A Phase 1, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MT-201 Administered With Concomitant Infliximab in Healthy Participants

Key Details

Gender

All

Age Range

19 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

25

Start Date

2026-07-16

Completion Date

2026-11-12

Last Updated

2026-08-20

Healthy Volunteers

Yes

Interventions

DRUG

MT-201

MT-201 and Infliximab

Locations (1)

Mirador Clinical Department

San Diego, California, United States